Abstract:Melasma is an acquired, symmetrical hypermelanosis of the face and is particularly seen in women with skin types IV to VI living in areas with intense UVR. So it is a great problem in our country. Treatment of melasma remains a challenge. Topical therapy with a triple combination topical agents appears to be the most clinically effective initial therapy for patients with melasma. A clinical trial was conducted to find out the efficacy of the triple combination of 4% hydroquinone, 0.05% tretinoin and 0.01% fluocinolone acetonide cream in the treatment of facial melasma. Fifty clinically diagnosed cases of melasma attending the Skin and VD outpatient department of General Hospital, Faridpur were selected randomly. Majority (54%) were between 21 to 25 years of age and most of them (86%) were female. After 20 weeks of treatment with triple combination agents, the average MASI score decreased significantly (P<.001). Reduction of the severity of melasma by 20 weeks is 82% and by 8 weeks is 71%. Regarding the distribution of melasma, 50% were found centrofacial, 45% malar and 5% mandibular. As side effects of the treatment, 36% developed erythema, 16% developed burning sensation, 6% developed pruritus and 4% developed desquamation. This study demonstrates that every night application of triple combination topical agent has significant effect on melasma.
Abstract:Vitiligo is an acquired, often progressive disorder of hypopigmentation. A lot of research has been conducted during the years yet its exact etiology still remains elusive. As a result even after so many years, there is no ideal treatment for vitiligo. Treatment options such as Narrowband Ultraviolet B (NB-UVB), Targeted Phototherapy, and Excimer laser on the medical front, in addition to epidermal cell transplantation and melanocyte culture transplants on the surgical front, have all revolutionized the management of this psychologically devastating disease.
The burden of scabies is highest in tropical countries, but recent data from Bangladesh is scanty. This cross sectional study was carried out to find the prevalence of scabies in skin & VD Out Patient Department (OPD) of Faridpur Medical College Hospital (FMCH) during the period of April 2013 to March 2014. Total 22,399 patients attended to the skin & VD OPD, were included in this study. We identified 15,455 patents with scabies. The total prevalence was 69%. Prevalence in January was highest & was 78%. Most cases were uncomplicated but 17.28% of complicated scabies patients were found. Scabies was more in poor socio-economic group than others. The present study showed a high prevalence of scabies in patients presenting to skin & VD OPD, FMCH. Prevalence was higher overall in children. Our data show that scabies is common in patients presenting to skin & VD OPD & this finding may be used as an indicator of the general population.Faridpur Med. Coll. J. Jan 2015;10(1): 17-19
:Scabies is one of the commonest diseases among all age groups. Topical permethrin is a widely used treatment option for scabies. Ivermectin is a newer oral agent for the treatment of scabies. This study was done to compare the efficacy of permithrin and oral Ivermectin in the treatment of Scabies in patient suffering from Diabetes mellitus. This comparative clinical trial was carried out in the outpatient department of Dermatology & Venereology, Diabetic Association Medical College Hospital (DAMCH), Faridpur from January 2012 to December 2012. A total 60 cases were enrolled purposively and divided into 2 groups. Group I received 2 doses oral Ivermectin and group II treated with 5% permethirn cream. Patients were followed up at the 3rd and 4th week. Total 86.6% patients of Ivermectin group and 90% of permethrin group were cured. Though permethrin showed somewhat more effective, the difference was not statistically significant. The study found that both ivermectin and permethrin were similarly effective in the treatment of scabies in patients suffering from Diabetes Mellitus.
Psoriasis is a chronic papulosquamous disorder with remissions and exacerbations. Varied estimates of the population prevalence of the disease in different parts of the world range from 0.1 - 3%. It is not uncommon in our country. Although there are no treatment options offering a complete cure, a number of options exist for providing symptomatic relief, inducing as well as prolonging remission. Various systemic therapies such as methotrexate, acitretin, cyclosporine, and biologic agents can be used. A review of pharmacokinetics, safety and a discussion of relapse rate establish acitretin, an aromatic retinoid as an efficacious, convenient, oral monotherapy for initial and maintenance of severe psoriasis. A prospective clinical trial was conducted to find out the efficacy and safety of acitretin as monotherapy in the treatment of moderate to severe plaque type psoriasis (PASI range 10-42). Thirty two clinically diagnosed cases of moderate to severe plaque type psoriasis attending the Skin and VD out patient department of Faridpur Medical College Hospital, Faridpur were selected randomly. Majority (46.9%) were between 61 to 80 years of age and only 3.1% patients were in the <20 years age group. The average age was 57.3 years and range was 19-90 years. Majority (68.8%) of the patients were male and 31.2% patients were female. The male female ratio was 2.2:1. After 8 weeks of treatment with acitretin PASI 50 and PASI 75 response rates were 55% and 24% respectively and after 12 weeks of treatment, PASI 50 and PASI 75 response rates were 75% and 50% respectively. As side effects of the treatment, 4(12.5%) patients developed alopecia, each of xerophthalmia and cheilitis was seen in 3(9.37%) patients, each of fatigue and pruritus was seen in 2(6.25%) patients and only 1(3.12%) patient developed myalgia. This study demonstrates that acitretin as monotherapy is effective and safe in the treatment of moderate to severe plaque type psoriasis. Faridpur Med. Coll. J. Jan 2019;14(1): 16-19
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.